VIDEO: Supplemental aflibercept did not influence outcomes of EYP-1901 in wet AMD
Click Here to Manage Email Alerts
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Carl D. Regillo, MD, discusses the impact of supplemental aflibercept on eyes with wet age-related macular degeneration treated with EYP-1901.
According to Regillo, a subgroup analysis of the phase 2 DAVIO 2 trial looked at the effect of supplemental injections after treatment with EYP-1901 (EyePoint Pharmaceuticals) on vision and anatomic outcomes.
“What we did is we compared eyes without supplements to the entire patient population in the EYP arms and did not see a difference, both in BCVA outcomes or OCT anatomic outcomes,” he said. “We can conclude that the supplemental injections that were performed in about a third of the patients in the EYP arms didn’t influence the outcomes.”
Regillo also discussed plans for a phase 3 registration trial on EYP-1901.
Collapse
Regillo CD. The DAVIO 2 trial: Subgroup data from a phase 2, multicenter study of a single injection of EYP-1901 (vorolanib in the Durasert E technology) vs aflibercept for previously treated wet age-related macular degeneration. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).
Read more about
Click Here to Manage Email Alerts